Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ubamatamab · REGN-4018

Bispecific antibody · Immune activation, directed at CD3 (CD3E) and MUC16 (CA125) (MUC16) · developed by REGENERON PHARMACEUTICALS

Phase 2 Most advanced trial
REGN Developer
1 Registered trials

What is Ubamatamab?

Ubamatamab is a bispecific human monoclonal antibody that binds human CD3 on T cells and MUC16 (CA125) on tumor cells. By cross-linking T cells to MUC16-expressing cells, it is intended to trigger a cytotoxic T-lymphocyte response against those cells. It is being studied in ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-4018
Drug type
Bispecific antibody
Targets
CD3 (CD3E), MUC16 (CA125) (MUC16)
Mechanism
Immune activation, directed at CD3 (CD3E) and MUC16 (CA125) (MUC16)
Pathways
T-cell cross-linking to tumor cells, cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
REGENERON PHARMACEUTICALS (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
6BUL1G4D60

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06787612 Phase 2 Ovarian Cancer Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Other drugs acting on CD3E / MUC16

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Ubamatamab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.